Globus Medical (GMED) Valuation Check After Updated Guidance And NuVasive Synergy Outlook

Simply Wall St.01-22

AdvertisementWhy Globus Medical’s latest guidance matters for shareholders Globus Medical (GMED) has put fresh numbers on the table, outlining expected sales for late 2025 and a revenue range for 2026...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605458485?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2026-01-22 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605458485","market":"hk","top_or_hot":-1,"title":"Globus Medical (GMED) Valuation Check After Updated Guidance And NuVasive Synergy Outlook","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Globus Medical’s latest guidance matters for shareholders Globus Medical (GMED) has put fresh numbers on the table, outlining expected sales for late 2025 and a revenue range for 2026...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/globus-medical-gmed-valuation-check-after-updated-guidance-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Globus Medical (GMED) Valuation Check After Updated Guidance And NuVasive Synergy Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlobus Medical (GMED) Valuation Check After Updated Guidance And NuVasive Synergy Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-22 06:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/globus-medical-gmed-valuation-check-after-updated-guidance-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Globus Medical’s latest guidance matters for shareholders Globus Medical (GMED) has put fresh numbers on the table, outlining expected sales for late 2025 and a revenue range for 2026...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/globus-medical-gmed-valuation-check-after-updated-guidance-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065732104.USD","symbol_name":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/globus-medical-gmed-valuation-check-after-updated-guidance-a","article_id":"2605458485","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/globus-medical-gmed-valuation-check-after-updated-guidance-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605458485","pubTimestamp":1769033720,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Globus Medical’s latest guidance matters for shareholders\nGlobus Medical (GMED) has put fresh numbers on the table, outlining expected sales for late 2025 and a revenue range for 2026 that builds on its integration of NuVasive and recent earnings momentum.\nSee our latest analysis for Globus Medical.\nGlobus Medical’s guidance has arrived alongside strong momentum in the share price, with a 90 day share price return of 49.08% and a 5 year total shareholder return of 46.66%. Together, these...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","GMED":"Globus Medical Inc","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4082":"医疗保健设备","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","NUVA":"纽瓦索器材"},"translate_title":"Globus Medical(GMED)更新指导和NuVasive协同展望后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMED":1.5,"NUVA":1.5,"DCF":1},"content_text":"AdvertisementWhy Globus Medical’s latest guidance matters for shareholders Globus Medical (GMED) has put fresh numbers on the table, outlining expected sales for late 2025 and a revenue range for 2026 that builds on its integration of NuVasive and recent earnings momentum. See our latest analysis for Globus Medical. Globus Medical’s guidance has arrived alongside strong momentum in the share price, with a 90 day share price return of 49.08% and a 5 year total shareholder return of 46.66%. Together, these figures point to building enthusiasm around its growth and NuVasive integration story. If this update has you rethinking the sector, it could be a good moment to see what else is happening across healthcare stocks and compare how other medical names are shaping up. With the shares up 49.08% over 90 days and trading at a roughly 19% intrinsic discount, is Globus Medical still mispriced, or is the market already factoring in the NuVasive synergies and potential growth story? Price-to-Earnings of 29.4x: Is it justified? Globus Medical is trading on a P/E of 29.4x, yet our DCF estimate of fair value at US$114.55 versus the last close of US$92.95 suggests a discount, and the stock also sits below the peer average P/E of 54.3x and the sector average of 31.2x. The P/E ratio compares the current share price with the company’s earnings per share and is a common way to see how the market values each dollar of profit. For a medical equipment name like Globus Medical, this multiple is often used to reflect expectations around future procedure volumes, product mix and margin profile. Here, the picture is mixed. On one hand, the shares are described as expensive relative to an estimated fair P/E of 22.1x, which implies the market is paying more than that regression based level for current earnings. On the other hand, the SWS DCF model fair value of US$114.55 and the current 18.9% discount to that estimate point to a share price that is below the cash flow based valuation anchor. Against peers, the 29.4x P/E sits clearly below the peer average of 54.3x and slightly below the US Medical Equipment industry average of 31.2x. This means the market is valuing Globus Medical’s earnings at a lower multiple than many comparable names, even though the fair ratio work suggests a level closer to 22.1x could be a point the market moves toward over time if earnings expectations cool. Explore the SWS fair ratio for Globus Medical Result: Price-to-Earnings of 29.4x (ABOUT RIGHT) However, the market’s enthusiasm could be tested if NuVasive integration synergies disappoint or if current P/E multiples compress across the wider medical equipment peer group. Find out about the key risks to this Globus Medical narrative. Another way to look at value While the P/E work paints GMED as roughly fairly priced against peers, our DCF model approaches the question from cash flows instead of earnings multiples and lands on a fair value of US$114.55 per share versus the current US$92.95. This implies the stock trades at an 18.9% discount. Which signal do you trust more when the two are not perfectly aligned? Look into how the SWS DCF model arrives at its fair value. GMED Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Globus Medical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 876 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Globus Medical Narrative If you see the numbers differently, or just want to stress test this view against your own work, you can build a custom story in minutes with Do it your way. A great starting point for your Globus Medical research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If Globus Medical has sharpened your thinking, do not stop here. The screener can surface other opportunities that might fit your style and portfolio goals.  Spot potential value candidates early by checking out these 876 undervalued stocks based on cash flows that line up with your preferred valuation metrics and risk tolerance. Tap into the growth potential of next wave technology by scanning these 23 AI penny stocks that could reshape how you think about long term themes. Strengthen your income stream by reviewing these 13 dividend stocks with yields > 3% that match your expectations for yield and payout consistency.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605458485","isCrawlerRequest":true}